ClinicalTrials.gov
ClinicalTrials.gov Menu

Milk Thistle in Pathological Gambling

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02337634
Recruitment Status : Recruiting
First Posted : January 13, 2015
Last Update Posted : October 26, 2017
Sponsor:
Information provided by (Responsible Party):
Jon Grant, University of Chicago

Brief Summary:
The goal of the proposed study is to evaluate the efficacy and safety of silymarin in individuals with gambling disorder. The hypothesis to be tested is that silymarin will be more effective and well tolerated in subjects with gambling disorder compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Condition or disease Intervention/treatment Phase
Pathological Gambling Gambling Disorder Drug: Placebo Drug: Milk Thistle Phase 2

Detailed Description:

Gambling disorder is a significant public health problem that often results in a distinctive pattern of persistent and disabling psychological symptoms. Although once thought to be relatively uncommon, studies estimate that gambling disorder has a lifetime prevalence among adults of 1.6% and past-year prevalence of 1.1%. Patients with gambling disorder also experience significant social and occupational impairment as well as financial and legal difficulties.

Individuals with gambling disorder report chronically high levels of stress, and vulnerability to gambling addiction is enhanced by stressful events (4), particularly as stress may result cognitive problems leading to impulsive and unhealthy decisions. A stress response is elicited when sensations and Observations do not match existing or anticipated expectations. A primary endocrine response to stress is the secretion of glucocorticoids through the activation of the hypothalamic-pituitary-adrenal axis. Although their release serves to maintain homeostasis during acute episodes of stress, prolonged stress responses have been associated with structural brain damage both in humans and animals. In humans, stress also enhances addictive craving, and relapse to addiction is more likely to occur in individuals exposed to high levels of stress. Since oxidative stress may be implicated in the etiology of addictive behaviors, use of antioxidants to reduce relapse, improve cognitive functioning, and reduce addictive urges may be a sensible step.

Silymarin, a flavonoid and a member of the Asteraceae family, is extracted from the seeds of milk thistle (Silybum marianum) and is known to own antioxidative and anti-apoptotic properties. Silymarin has been reported to decrease lipid peroxidation. Furthermore, it has been demonstrated that its anti-oxidative activity is related to the scavenging of free radicals and activation of anti-oxidative defenses: increases in cellular glutathione content and superoxide dismutase activity. Milk thistle has been used for a range of psychiatric disorders including methamphetamine abuse and obsessive compulsive disorder, two psychiatric disorders with similarities to gambling disorder. The flavanoid complex silymarin in preclinical studies has been found to increase serotonin levels in the cortex, and ameliorate decreases in dopamine and serotonin in the prefrontal cortex and hippocampus associated with methamphetamine abuse. In the frontal cortex one of the functions of dopamine is to increase the signal to noise ratio, increased dopamine correlating with increased frontal performance. Studies have shown that the higher cortical dopamine levels are associated with improved frontal cortical cognitive performance. Cortical inhibition is felt to be the basis for top-down control of motivated behaviors. A recent randomized controlled study with milk thistle was conducted in Iran Thirty five participants with moderate OCD were randomly assigned to 200 mg of milk thistle leaf extract or 10 mg of fluoxetine three times daily for eight weeks. Results revealed no significant difference in treatment effects between milk thistle and fluoxetine from baseline to endpoint as both interventions provided a highly significant reduction in symptoms.

Silymarin or Milk Thistle may therefore offer promise for the treatment of individuals with gambling disorder. Pharmacological management of gambling symptoms has produced mixed results, with some studies showing a superiority of medication to placebo.

The current pilot study examines the tolerability and efficacy of milk thistle in the treatment of gambling disorder. We hypothesize that milk thistle will reduce the severity of gambling symptoms and improve patients' overall functioning.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study
Study Start Date : January 2015
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : October 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Matched dosage of milk thistle daily.
Drug: Placebo
Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Other Name: Sugar Pill

Active Comparator: Milk Thistle
Capsule form, 150mg BID to 300mg BID
Drug: Milk Thistle
Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Other Name: Silymarin




Primary Outcome Measures :
  1. Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. Every 2 weeks the subject will take the PG-YBOCS for the duration of the 8 weeks. At each of these visits the outcome will be assessed. The scale itself assess severity of gambling.


Secondary Outcome Measures :
  1. Clinical Global Impression-Improvement and Severity scales (CGI) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. Every 2 weeks the subject will take the CGI for the duration of the 8 weeks. At each of these visits the outcome will be assessed. The scale itself assess overall disorder severity.

  2. Gambling Symptom Assessment Scale (G-SAS) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. Every 2 weeks the subject will take the G-SAS for the duration of the 8 weeks. At each of these visits the outcome will be assessed. The scale itself assess severity of gambling symptoms.

  3. Hamilton Anxiety Rating Scale (HAM-A) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. Every 2 weeks the subject will take the HAM-A for the duration of the 8 weeks. At each of these visits the outcome will be assessed. The scale itself assess levels of anxiety.

  4. Sheehan Disability Scale (SDS) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. Every 2 weeks the subject will take the SDS for the duration of the 8 weeks. At each of these visits the outcome will be assessed. The scale itself assess level of disability resulting from gambling (or target disorder)

  5. Hamilton Depression Rating Scale (HAM-D) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. Every 2 weeks the subject will take the HAM-D for the duration of the 8 weeks. At each of these visits the outcome will be assessed. The scale itself assess level of depression.

  6. Perceived Stress Scale (PSS) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. Every 2 weeks the subject will take the PSS for the duration of the 8 weeks. At each of these visits the outcome will be assessed. The scale itself assesses the level of perceived stress the individual experiences.

  7. Quality of Life Inventory (QOLI) [ Time Frame: Once every two weeks for the 8 weeks of the study ]
    The entire study for an individual subject will last 8 weeks. This inventory will be completed at the first and last visit of the study, with only these two points being assessed. The scale itself assess the subjects overall perceived quality of life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women age 18-75;
  • Diagnosis of current gambling disorder based on DSM-5 criteria and confirmed using the clinician-administered Structured Clinical Interview for Pathological Gambling (SCI-PG) (12);
  • Gambling behavior within 2 weeks prior to enrollment;
  • Women of child bearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;
  • Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence

Exclusion Criteria:

  • Infrequent gambling (i.e. less than one time per week) that does not meet DSM-5 criteria for gambling disorder;
  • Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;
  • History of seizures;
  • Myocardial infarction within 6 months;
  • Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
  • A need for medication other than milk thistle with possible psychotropic effects or unfavorable interactions as determined by the investigator;
  • Clinically significant suicidality (defined by the Columbia Suicidal Scale);
  • Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder;
  • Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;
  • Previous treatment with milk thistle

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02337634


Contacts
Contact: Eric W Leppink, B.A. 773-834-3778 eleppink@yoda.bsd.uchicago.edu

Locations
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Jon E Grant, JD, MD, MPH    773-834-3778      
Principal Investigator: Jon E Grant, JD, MD, MPH         
Sponsors and Collaborators
University of Chicago
Investigators
Principal Investigator: Jon E Grant, JD, MD, MPH University of Chicago

Responsible Party: Jon Grant, Professor, University of Chicago
ClinicalTrials.gov Identifier: NCT02337634     History of Changes
Other Study ID Numbers: 14-0480
First Posted: January 13, 2015    Key Record Dates
Last Update Posted: October 26, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Gambling
Disruptive, Impulse Control, and Conduct Disorders
Mental Disorders
Silymarin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs